http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#head http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8 http://www.nanopub.org/nschema#hasAssertion http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#assertion http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8 http://www.nanopub.org/nschema#hasProvenance http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#provenance http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8 http://www.nanopub.org/nschema#hasPublicationInfo http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#publicationInfo http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#assertion http://bio2rdf.org/drugbank:DB06193 http://bio2rdf.org/bio2rdf_vocabulary:identifier DB06193 http://bio2rdf.org/drugbank:DB06193 http://bio2rdf.org/bio2rdf_vocabulary:namespace drugbank http://bio2rdf.org/drugbank:DB06193 http://bio2rdf.org/bio2rdf_vocabulary:uri http://bio2rdf.org/drugbank:DB06193 http://bio2rdf.org/drugbank:DB06193 http://bio2rdf.org/bio2rdf_vocabulary:x-identifiers.org http://identifiers.org/drugbank/DB06193 http://bio2rdf.org/drugbank:DB06193 http://bio2rdf.org/drugbank_vocabulary:drugbank-id DB06193 http://bio2rdf.org/drugbank:DB06193 http://bio2rdf.org/drugbank_vocabulary:x-cas http://bio2rdf.org/cas:784209-05-8 http://bio2rdf.org/drugbank:DB06193 http://bio2rdf.org/drugbank_vocabulary:x-wikipedia http://bio2rdf.org/wikipedia:Pixantrone http://bio2rdf.org/drugbank:DB06193 http://purl.org/dc/terms/description Pixantrone is an aza-anthracenedione and DNA intercalator which inhibits topoisomerase II. It is similar in structure to anthracyclines such as mitoxantrone, but exerts fewer toxic effects on cardiac tissue. [2] The lower cardio-toxic effects of pixantrone may be explained, in part, by its redox inactivity [3]. Pixantrone does not bind iron and promotes the formation of reactive oxygen species to a lesser degree than other anthracyclines. It also inhibits doxorubicinol formation in human myocardium. [3] As a result, it is believed to be less cardiotoxic while still exerting efficacy. Pixantrone was designed to treat relapsed or refractory aggressive non-Hodgkin's lymphoma(NHL) in patients who have failed two prior lines of therapy. [2] For patients suffering from NHL, first line therapies consist of anthracycline containing multi-drug treatments which unfortunately are known to cause irreversible myocardial tissue damage. Patients refractory to treatment, or those who relapse, are discouraged from further anthracycline use due to cumulative cardiotoxicity. Pixantrone dimaleate, administered intravenously, was designed by Cell Therapeutics Incorporated as an alternative second line therapy in refractory or relapsed NHL. It is currently being tested in Phase III trials. [2] Although pixantrone has not yet received FDA approval in the United States, it has been granted conditional marketing approval by the European Union. Conditional approval was granted by the European Medicines Agency after a phase III EXTEND trial of patients with NHL showed that pixantrone was tolerable and that it resulted in significantly higher complete response rate and progression free survival in comparison to other single chemotherapy agents. However, it is notable that the EXTEND trial was stopped early, leaving the statistical significance of the results in question. Based on this uncertainty, in 2009, the FDA ultimately rejected Cell Therapeutic's initial application for accelerated approval for pixantrone use in relapsed or refractory NHL. Another phase III trial, PIX-R, is now ongoing to clarify pixantrones place in therapy. It will compare pixantrone efficacy to that of gemcitabine. [2] http://bio2rdf.org/drugbank:DB06193 http://purl.org/dc/terms/identifier drugbank:DB06193 http://bio2rdf.org/drugbank:DB06193 http://purl.org/dc/terms/title Pixantrone http://bio2rdf.org/drugbank:DB06193 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://bio2rdf.org/drugbank_vocabulary:Drug http://bio2rdf.org/drugbank:DB06193 http://www.w3.org/2000/01/rdf-schema#label Pixantrone [drugbank:DB06193] http://bio2rdf.org/drugbank:DB06193 http://www.w3.org/2000/01/rdf-schema#seeAlso http://www.drugbank.ca/drugs/DB06193 http://bio2rdf.org/drugbank:DB06193 http://www.w3.org/2000/01/rdf-schema#seeAlso http://www.drugs.com/history/pixuvri.html http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#provenance http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz http://bio2rdf.org/drugbank_resource:bio2rdf.dataset.drugbank.R3 http://www.w3.org/ns/dcat#distribution http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz http://purl.org/dc/terms/created 2015-01-09T17:00:50-05:00 http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz http://www.w3.org/ns/prov#wasDerivedFrom http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00 http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00 http://purl.org/pav/retrievedOn 2014-11-12T07:57:03-05:00 http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00 http://www.w3.org/ns/prov#wasDerivedFrom http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip http://www.w3.org/ns/prov#wasAttributedTo http://drugbank.ca http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#publicationInfo http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#signature.MCwCFErrmXRa0t5w http://purl.org/nanopub/x/hasPublicKey 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 http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#signature.MCwCFErrmXRa0t5w http://purl.org/nanopub/x/hasSignature MCwCFErrmXRa0t5wyVahYpBfhPydw8L6AhQF4wZ2KdND2fuOjKic3ge0SPQL3Q== http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#signature.MCwCFErrmXRa0t5w http://purl.org/nanopub/x/signedBy https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8 http://purl.org/dc/terms/created 2018-03-30T11:10:46.888+02:00 http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8 http://purl.org/dc/terms/license https://creativecommons.org/licenses/by-nc/4.0/ http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8 http://purl.org/nanopub/x/hasSignatureElement http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8#signature.MCwCFErrmXRa0t5w http://bio2rdf.org/drugbank:DB06193_nanopub.RAg3_8insaaOQTGtJEa8qTpLyL2vvJVkVzSr0WLcq9uE8 http://www.w3.org/ns/prov#wasGeneratedBy https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://www.w3.org/ns/prov#specializationOf https://github.com/tkuhn/bio2rdf2nanopub https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://www.w3.org/ns/prov#wasAttributedTo http://orcid.org/0000-0002-1267-0234 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475 http://purl.org/dc/terms/identifier 7720f136-841b-4851-a6e4-ad20a409a475 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475 http://www.w3.org/ns/prov#used https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475 http://www.w3.org/ns/prov#wasAssociatedWith https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475 http://www.w3.org/ns/prov#wasStartedBy http://orcid.org/0000-0002-1267-0234 https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://purl.org/dc/terms/isVersionOf https://github.com/tkuhn/bio2rdf2nanopub https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://purl.org/pav/version eda7951a5f6c622c5d2132f50c3093138484a349 https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://www.w3.org/ns/prov#wasAttributedTo http://orcid.org/0000-0002-1267-0234